IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 36 filers reported holding IMPEL NEUROPHARMA INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,836 | -66.1% | 25,200 | 0.0% | 0.00% | – |
| Q2 2023 | $32,004 | -9.3% | 25,200 | 0.0% | 0.00% | – |
| Q1 2023 | $35,280 | -87.5% | 25,200 | -66.4% | 0.00% | – |
| Q4 2022 | $281,250 | +38.5% | 75,000 | +79.9% | 0.00% | – |
| Q3 2022 | $203,000 | -47.8% | 41,700 | 0.0% | 0.00% | – |
| Q2 2022 | $389,000 | -66.1% | 41,700 | -76.8% | 0.00% | – |
| Q1 2022 | $1,147,000 | -21.3% | 180,045 | +6.6% | 0.00% | – |
| Q4 2021 | $1,458,000 | -7.2% | 168,938 | +31.0% | 0.00% | – |
| Q3 2021 | $1,571,000 | +283.2% | 128,974 | +178.6% | 0.00% | – |
| Q2 2021 | $410,000 | – | 46,298 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| 5AM Venture Management, LLC | 2,884,791 | $24,896,000 | 4.67% |
| venBio Partners LLC | 2,759,791 | $23,817,000 | 4.29% |
| Vivo Capital, LLC | 2,884,789 | $24,896,000 | 1.50% |
| LASRY MARC | 330,000 | $2,848,000 | 1.41% |
| DCF Advisers, LLC | 256,027 | $2,210,000 | 0.90% |
| Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $35,693,000 | 0.20% |
| EPIQ PARTNERS, LLC | 18,646 | $161,000 | 0.09% |
| Anson Funds Management LP | 17,729 | $153,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 78,300 | $676,000 | 0.01% |
| TRUSTCORE FINANCIAL SERVICES, LLC | 13,407 | $116,000 | 0.01% |